⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KPTI News
Karyopharm Therapeutics Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
accessnewswire.com
KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
accessnewswire.com
KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
accessnewswire.com
KPTI
Form 8-K
sec.gov
KPTI
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
prnewswire.com
KPTI
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
prnewswire.com
KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
prnewswire.com
KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
accessnewswire.com
KPTI
Form 8-K
sec.gov
KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
KPTI